For January 2024, Exploristics is pleased to be launching the Pulmonary Suite, a collection of robust pulmonary disease specific data models for targeted clinical trial design optimisation. The suite contains accurate, ready-to-use historical data for eleven pulmonary diseases, providing a broad and deep overview of the pulmonary clinical trial landscape, clinical outcomes, and patient characteristics. To date the suite contains information from 23,402 clinical trials, 384,736,305 participants and 404,099 data points. It includes data models for:
- pulmonary artery hypertension
- idiopathic pulmonary fibrosis
- cystic fibrosis
- chronic obstructive pulmonary disease
- asthma
- COVID-19
- bronchiectasis
- influenza
- non-small cell lung cancer
- rhinovirus
- respiratory syncytial virus
Using Exploristics Data Science Services, the Pulmonary Suite can be searched and used to inform key clinical study assumptions such as endpoints, biomarkers and patient populations when designing a clinical trial. Leveraged in state-of-the-art simulation guided design platform, KerusCloud, the suite supports extensive optimisation of clinical trial design. This targeted data-driven design approach is a highly effective strategy for de-risking real clinical trials. Studies designed in this way have been shown to achieve a >77% chance of success, far exceeding historical pharmaceutical industry study success rates. Bespoke disease specific data models for any indication are also available on request for use with KerusCloud.
Exploristics CEO (Chief Executive Officer), Aiden Flynn said “The Pulmonary Suite delivers yet another significant milestone for Exploristics to truly revolutionise respiratory trial design. Used in KerusCloud, it delivers quantitative insights that support data-driven design decisions to significantly de-risk real clinical studies. This has been shown to increase study success three-fold, while reducing patient burden, development costs and timelines. Having pre-built data models reduces the timelines for simulations from weeks to hours/days. In addition, the automated tools we have developed allow us to build bespoke data models very quickly.”
Exploristics CDSO (Chief Data Scientific Officer), Kim Hacquoil said “With the Pulmonary Suite, clinical research teams are now able to tackle, with confidence, the multiple complex challenges involved in designing effective studies for their respiratory asset. The suite offers developers of any size robust historical data to inform a powerful de-risking simulation approach for designing studies that is very cost-effective. As a result, the Pulmonary Suite is the latest must-have component for the trial design toolkit.”
To find out more about the Pulmonary Suite, please visit https://exploristics.com/pulmonary-disease-specific-data-models/.
To find out more about KerusCloud and how simulation-guided design is shaking up clinical trial design, please visit https://exploristics.com/keruscloud-platform-overview/.